Author Archive for Pharmboy

Monoclonal Antibodies (Part 2)

Reminder: Pharmboy is available to chat with Members, comments are found below each post.

Monoclonal Antibodies (Part 2)

(See also: Monoclonal Antibodies Part 1)

Courtesy of 

In Part 1 of Monoclonal Antibody Companies, I highlighted a leader in the field, Seattle Genetics (SGEN). It's technology incorporates monoclonal antibodies (mAb), and also allows for having a drug ‘tagged’ on the mAb, so that when the mAb attaches to a cell, it is ‘ingested’ into the cell, and the drug is released. The antibody-drug combination is called an antibody-drug conjugate (ADCs). ADCs are "empowered" antibodies. They are designed to use the targeting ability of the antibody to precisely deliver the toxic drug where it's needed, increasing its effectiveness and decreasing side effects.

Think of the technology as a bunker buster bomb, that is guided by a laser, hits its target, penetrates, and then destroys all from within.  Seattle Genetics has licensed its technology to several companies. Other companies are involved in this kind of research as well.

Antibodies are used by the immune system to clear pathogens from the body. The antibody protein is in the shape of a Y, where the trunk is the effector region (similar in most antibodies) and the ends of the Y are the variable regions (paratope) that bind the pathogen (antigen).

Antibodies are produced by B-cells and used by the immune system to identify and neutralize foreign material such as bacteria and viruses. There are several types of antibodies made for the defense of the body. (More here)

ImmunoGen, Inc. (IMGN, $12.92) was a pick several years ago…
continue reading





Biotechs Galore – A Few For Consideration

Reminder: Pharmboy is available to chat with Members, comments are found below each post.

Biotech Corner: Monoclonal Antibody Companies (Part 1)

From The latest Market Shadows newsletter: A Failure to Communicate: Numbers, Rates & Lies

By Pharmboy

Biotech stocks are my passion. My alter-ego is a scientist, working in the field of biotech, and I love it.

The days of becoming the next Genentech or Amgen are over. Big Pharma will become the juggernauts that will sell and market the drugs, while smaller companies will fill the pipelines and keep the juggernauts running.  Premiums being paid to buy phase 1 compounds are increasing. Phase 1 includes all preclinical testing. The larger companies are paying 100M for phase 1 compounds, whereas it only takes about 25M to get to phase 1. (Phase 1 compounds are those that have completed very early trials, but for which there is no efficacy data yet.)

Typically, biotechs are more efficient than Big Pharma companies. The return on investments for biotech companies, if they are efficient and successful, is north of 300%. That is not a bad return….but biotechs are high risk and often have many failures that eat into those potential gains.

I am going to focus on a few companies that have a communal relationship to a technology – the monoclonal antibody (mAb) technology. Monoclonal antibody technology had its first success in 1986, when muromonab was approved for transplant rejection. mAb’s are specific to a particular target.  When a mAb binds to its target, it stimulates an immune response. The immune system then attacks the target and ‘kills’ the target.

Monoclonal Ab technology has exploded, with ‘tags’ now being attached to the mAb. Those tags can be radionucleotides, anti-neoplastic agents, other antibody-drug conjugates (ADC), and other proteins.  All of these tags are released when the mAb binds to its target, the conjugates then perform their actions. There is a very good review here.

 

 

There are several companies that have employed the technology of attaching a drug (ADC) to their specific mAb. One company that has both in-house and licensed-out technology is Seattle Genetics (SGEN, $25.31). SGEN is poised for growth – IF a few of its mAb’s prove to be effective in treading various blood cancers. The company licenses out its technology to Roche (Genentech), Celldex (CDLX), Progenics (PGNX), Abbott (ABT), Astellas and many other companies for various types of cancer.…
continue reading





Phil’s Stock World – Vegas Style

Reminder: Pharmboy is available to chat with Members, comments are found below each post.

Greetings members….and welcome back from a fabulous time in Vegas, and then a little time for a Thanksgiving filled with friends and family. 

PSW in Vegas had a great turn out, and lots of questions were asked and answered by Phil, Craigzooka, Ron and Pharm.  A very big thanks to Savi and LVModa for making the time spent efficient and productive!  Now, on to a summary of the presentations.

As always, for any new members, things started off with how to manage a portfolio.   The amount that the portfolio has in it is not important, it is how those funds are deployed.  When first joining PSW, many think that they should jump right in and start trading with Phil and the like, as every trade appears like a winner.  But, that is not what the board is about….it is about sustaining our funds, and letting it grow through time.

With that in mind, The Man Who Planted Trees is where to start the PSW experience.

 

 

Instead of writing a summary about the video, take the time to watch it.  Think about its message, and how it relates to your investing style.

Being in Vegas, Phil pointed out that the city was built on "being the house."  The stock market is nothing more than gambling.  One 'invests' in companies 'betting' that the value of that investment will grow with time.  If one invests in a stock, why not collect rent on that investment – selling calls and puts against the position.  If the company pays a dividend, then that is an added bonus.  By selling 'premium,' one is being the house.  When selling the puts, though, it is important to remember that one better 'damn' well want to own the stock at that price, or have a counter move to buffer any potential moves in the stock price.  Hence, the buy-write method, where one can own the stock for a 20% discount.

This is a simple way to invest (gamble), and it is good to re-evaluate every month or so if the positions are long term buy-writes – meaning out 3 mo or more.

A side note:  Apple (AAPL)…
continue reading





Still Here, Just Waiting…..Biotechs Are In a Holding Pattern

Reminder: Pharmboy is available to chat with Members, comments are found below each post.

A few months have passed since my last post, as there has been things happening in the biotech world, but nothing 'new' enough to jump on board and get behind.  Drug development is a long, arduous process, and clinical trials are the worst.  The smaller the diseases are in a population, the longer it takes to enroll, test and then post results. 

At PSW, we have been patient investors in MITI (bought by Amgen), CRIS, EXEL, SGEN and many others, and waiting in the wings are CLDX, YMI, and now PGNX.  I noted several years ago, that cancer and neuroscience are the final frontiers to conquer, and they remain today where they were then…so time does not change things that fast!  Diabetes and cardiovascular diseases are pretty well served with existing therapies, and yes, there will be a few that creep into the space, but overall these diseases needs are met.  The hottest areas in pharma today remain small, elusive, and lucrative diseases that demand a premium – cancer and fibrosis.

Fibrosis is another topic, and in the next few months, an article or two will go over some new therapies for fibrosis, which can manifest itself in several different disease types (IPF, kidney, scleroderma, etc).  For now, this article will focus on cancer treatments, and more specifically, monoclonal antibodies (mAbs) that have attached to them a chemotherapeutic.

First, a short summary on mAbs and how they work. 

Antibodies are used by the immune system to clear pathogens from the body.  The antibody protein is in the shape of a Y, where the trunk is the effector region (similar in most antibodies) an the ends of the Y are the variable regions (paratope) that bind the pathogen (antigen). 

Antibodies are produced by B-cells that is used by the immune system to identify and neutralize foreign objects such as bacteria and viruses. There are several types of antibodies made for the defense of the body, and they can be read about here.

Scientists figured out how to manufacture antibodies to a specific antigen in the late 1970s, but…
continue reading





2012 Vegas Information for PSW Members

Reminder: Pharmboy is available to chat with Members, comments are found below each post.

 

Last year, members gathered around a few tables and enjoyed meeting each other and listening to all our recent disasters on investing.  Phil talked about managing portfolios, and rambled here and there about how great Pharmboy was ( :) ).  No, really, the time was well spent, LVModa put on a good venue for us to eat, drink, chat, and most importantly, learn.

This year we hope to have more members show up and give their take on trading, investing, as well as just meet who is whom behind the mask. Details are noted below on who, where, and when.

Who:  PSW memebers – open to anyone who want wants to pay Savi

Where:  Las Vegas – many stayed at the Vdara, but the meetings took place at Cafe Moda LV, 3400 South Jones Blvd, Las Vegas, NV 89146

When:  November 10-12

  • Saturday Night ~7 meet for dinner (dutch payment, probably Nobu) also poker for those interested.
  • Sunday 11 am – lunch at Cafe Moda, Meeting until about 4

    • Opening Remarks – Phil
    • BBBW – Ron
    • TA & Pharma Investing – Pharmboy
    • Open Mike!
  • Monday 6 am – breakfast and be there before the market opens until market closing (about 1 pm)

Costs: $200 deposit, minimum of 25 members, maximum 50 members.  Money pays for Cafe Moda venue, internet access, lunch (Nov 11) and breakfast (Nov 12).

Pay Savi S. via Paypal.  Contact info is savi_ted at hotmail dot com





Big Pharma Review Part 2

Reminder: Pharmboy is available to chat with Members, comments are found below each post.

Throughout the global pharmaceutical industry, 47% of respondents are ‘more optimistic’ about revenue growth for their company over the next 12 months relative to the previous 12 months.  A further 28% of respondents are ‘neutral’ about revenue growth as compared with 23% who are ‘less optimistic’ about their company’s revenue prospects (InfoGrok).  China is expected to continue to be a large part of the industry's growth, where the EU (obviously) is expected to slow down.  Overall, though, the pharma industry is still working through its patent cliff, with the final last call for a few blockbusters (The Calm Before the Storm). 

This is the second installment of the Big Pharma Review where the pipelines of GlaxoSmithKline, Novartis, Eli Lilly, Sanofi, and AstraZeneca will be updated/discussed (Part 1 is here).

GlaxoSmithKline (GSK) has been in the headlines recently for its desire to acquire Human Genome Sciences for $13/share ($2.6B).  The company has plenty of cash, and it is not like it cannot afford HGSI, as GKS has a market capitalization of $114B. The company generates revenue of $43B and has a net income of $8.6B.  GSK has also increasing its stake in Theravance (THRXarticle on THRX here), and bought a German company, Cellzome, which uses a proteomics technology to analyze the efficiency of a drug and for safety profiling research.

The company's flagship products are in respiratory (Seretide/Advair (named Beyond Advair) and Avodart).  In recent news, two experimental melanoma medicines (dabrafenib and trametinib) slowed the progress of cancer with few skin complications in an early study.   Dabrafenib works by inhibiting BRAF, a mutant gene that spurs cancer cell growth in about half of melanoma patients, while trametinib is designed to thwart a related protein called MEK, which helps tumors resist an assault on BRAF.  The drug combination had a lower incidence of rash and skin lesions than had been previously reported with Roche’s Zelboraf, according to a study of 77 patients with advanced melanoma, the most-severe form of skin cancer.

Vaccines, cardiovascular and dermatology (with its Stifel acquisition from a few years ago) will continue to drive growth.  David Redfern of JPM has a very…
continue reading





Big Pharma – Where Are We Now?

Reminder: Pharmboy is available to chat with Members, comments are found below each post.

In this article, please revisit an article written two years ago titled, "The Calm Before the Storm."  This article focused on the patent cliff that was looming in the pharmaceutical industry, that was later picked up by the New York Times and several other bloggers!  Subsequent articles were written about big pharma company's revenue streams, and the pros and cons of of their later stage pipelines.  Other articles have also attempted to identify smaller biotechs with the potential to reap big rewards, because these biotechs are possible acquisition candidates by the big pharma companies that need to fill their coffers with new, multi-billion dollar drugs -  the so called "blockbusters."

Forbes has an informative article that projects three different revenue scenarios in in the pharmaceutical industry. Forbes's last figure (below) shows what companies will best weather the storm by combining "total company revenues."

In the 'Storm' article, it is noted that pharma growth rates should be growing less or starting to stall into 2014 due to the patent cliffs (see Table 1).  A few examples of slow growing revenue streams are (2010 -2011): Pfizer $67.1B to $67.4B; Merck $46B to $48B, JNJ $62B to $62B, and AMGN $15.1 to $15.5.  The industry is still ripe for consolidation based upon forward earnings, and the numbers of blockbusters will be dwindling.  The industry is taking on more risk in therapy areas that are unmet medical needs, but have fewer patients to treat – thus higher prices will ensue.  Monoclonal antibodies (mAb) for cancer and other 'biologics' fit this pricey niche area.

Table 1. Patent Cliff 2010 – 2012
Company Drug Indication Sales in $B (2009) Patent Expiration
Pfizer/Eisai Aricept Alzheimer’s 1 2010
Merck Cozaar Hypertension 3.6 2010
Pfizer Lipitor Cholesterol 12.5 2011
JnJ Levaquin Antibiotic 1.5 2011
Sanofi/BMS Plavix Anticoagulant 9.3 2011
AstraZeneca Seroquel Antipsychotic 4.9 2011
Lilly Zyprexa Antipsychotic 4.9 2011
Merck Singulair Asthma 4.7


continue reading





Pharmboy in Technically Speaking

Reminder: Pharmboy is available to chat with Members, comments are found below each post.

Excerpt from Stock World Weekly, Technically Speaking, April 22, 2012. 

Courtesy of Pharmboy

That was a nice selloff – one that we have been waiting for, and there may be more to come! This gives us an opportunity to start easing into a few more positions that are already in our virtual portfolio. The virtual portfolio had a few options that we sold and that expired worthless this month: the PLX $5 April 2012 puts, and the INFI $5 April 2012 puts. 

Protalix BioTherapeutics, Inc. (PLX, $6.78) has an FDA decision coming up, and we have several positions in it still open. I’m waiting for the decision. For those that like to gamble on risky events, the May $7.5 calls make a good risk/reward for $0.80 cents. I like selling the $10 calls for $0.25 cents, which limits the upside, but also reduces the cost to $0.55 cents for the spread. 

OPKO Health, Inc. (OPK, $4.99) is another biotech I like at current prices. Scott Brown at Sabrient has also featured OPK as an insider buying play in Stock World Weekly’s April 1 issue:

Scott sent in two long trade ideas for this week’s newsletter. First, Scott likes OPKO Health Inc. (OPK, $4.73) because of the repeated insider buying of the stock. “55 buys this year … almost daily.” Scott shared an interview with Dr. Phillip Frost, OPKO’s Chairman and CEO, on Seeking Alpha, by John Eastman. Here’s the introduction:

“‘OPKO Health Inc. Is a pharmaceutical and diagnostics company headquartered in Miami, FL that develops and commercializes novel and proprietary technologies that include molecular diagnostics tests, vaccines to diagnose, treat, and prevent neurological disorders, infectious diseases, oncology, and ophthalmologic diseases. The company works in the United States, Chile, and Mexico and is headed by Phillip Frost, M.D…’ Continue reading the interview with Dr. Frost here.

OPK’s CEO continues to accumulate shares, and the stock is trading at around $5. I think selling the September $5 call and put for $1.20 combined, coupled with the purchase of shares, has a good risk/reward profile.

As for other new trades:

Vertex Pharmaceuticals (VRTX, $36.58) was already a winner once, and I think the time is ripe to start scaling in for owning shares of this company longer term. I like selling one…
continue reading





VVUS and ARNA

Reminder: Pharmboy is available to chat with Members, comments are found below each post.

By Pharmboy at Phil's Stock World

Excerpt from Stock World Weekly, Tightening the Screws

I expect the market to continue pulling back. But biotechs should mostly hold their ground. There are a few catalysts coming up, including with the companies Vivus and Arena. Both companies have been focusing on the obesity market. VVUS has Qnexa (a combination pill of phentermine and topiramate) and ARNA has Lorqess (a novel 5-HT2c receptor agonist).

Catalyst 1 – Vivus's stock (VVUS, $22.53) rocketed up on the PDUFA thumbs up (PDUFA = Prescription Drug User Fee Act – a group of doctors and experts meet to express their opinion about a drug). The FDA usually follows the experts’ recommendation, but not always. The FDA has yet to rule. A ruling should happen on or before April 17, 2012.

For VVUS, I like playing for a failure, as the risks to me outweigh any benefits. A very conservative GAMBLE is buying an April 2012 $20/$19 bull put spread for $0.30 or less.

Catalyst 2 – Arena (ARNA, $3.07) had a strong run from the $1.20 range, and now trades at $3.

ARNA has a PDUFA date set for June 27, 2012. If VVUS gets approval, ARNA should fair well. If VVUS is rejected, ARNA still has a chance to do well due to its drug having a different mechanism, as well as due to the patent life on its molecule.

For ARNA, I like playing a July 2012 $2.50/$3.50 bull call spread for $0.35 or less. 

Trades on these companies are all- or- none scenarios – i.e., RISKY.

 





Let’s Review: My Favorite Biotechs

Reminder: Pharmboy is available to chat with Members, comments are found below each post.

 

Good day PSW Members!  It has been a while since the last post, but biotech plays have been active in chat, as well as in Stock World Weekly with new trades, and updating existing ones.  I must say that the biotechs and pharma are doing well in my portfolio!  This article is mainly for the many new members that have joined the PSW chat over the past few months, as many of us oldie' but goodies are in the stock plays below in some form or another.

It remains my belief that the next few years are going to be big years for biotechs.  Pharma has expiring patents, and the big players continue to scour the landscape for up and coming companies and therapies.  One we played was MITI, and that was a nice winner for a longer term hold.  At PSW, buying and selling biotechs as day trades is not the style, as we invest in companies for longer term holds, or play them into major events, then reduce our risks/exposers using options and hedging strategies.

At the end of January, Infinity Pharma (INFI) dropped like a rock and we jumped an a conservative buy write that was a bit too conservative (bought the stock and sold the April $8/7 strangle).  INFI's stock is now above where it was when it dropped, amazing but this is how we like to enter biotechs, as if we bought at $10, well, it may not have recovered…..but that is water under the bridge now.  The company has 3 development candidates described below:

  • Saridegib (also known as IPI-926) is a novel, potent, oral molecule that inhibits Smoothened, a key component of the Hedgehog pathway.  The chemical is semi-synthetic derivative of the alkaloid cyclopamine.  The hedgehog pathway was noted in the Curis article here
  • Retaspimycin hydrochloride (also known as IPI-504) is an intravenously administered, potent and selective heat shock protein 90 (Hsp90) inhibitor.  HSP90 is a chaperone to other proteins – in other words, they help in the folding or unfolding of proteins as they are being made or broken down.  Think of them as the arm in a car assembly line that aid in the production or destruction of the automobile.  In cancer, HSP90 helps stabilize proteins that are upregulated in cancer.  


continue reading





 
 
 

Market News

News You Can Use From Phil's Stock World

 

Financial Markets and Economy

The Jobs Report and the August Curse: Jobs Day Guide (Bloomberg)

The stakes couldn't be higher for the August employment report, even though the month has typically been cursed by disappointment.

For Federal Reserve officials, who are trying to gauge the U.S. economy's prospects as they consider raising interest rates in less than two weeks, have already been thrown a curve ball — global economic malaise and reeling financial markets.

Canada Oil Sands Fork Over Billions for 500,000 Unneeded ...



more from Paul

Phil's Favorites

Meet "Buzz" Draghi: To Infinity and Beyond

Courtesy of Mish.

Mario Draghi, Monetarist Mule

The never-ending push for 2% price inflation is absurd to the point of being counterproductive.

However, stubborn central bank mules don't care about history or common sense. They just keep doing what their fatally flawed model says they should do.

The ECB's stubborn mule, a Downbeat Draghi, is Ready to Beef Up Quantitative Easing Package.
The euro and eurozone government bond yields plunged on Thursday after the ECB president indicated it stood ready to extend the “size, composition and duration” of its €1.1tn bond-buying programme.

“We are observing a weakening of the prospects of the Chinese economy,” Mr Draghi said. “Th...



more from Ilene

Zero Hedge

Paul Craig Roberts: The Rise Of The Inhumanes

Courtesy of ZeroHedge. View original post here.

Submitted by Tyler Durden.

Submitted by Paul Craig Roberts,

America’s descent into totalitarian violence is accelerating. Like the Bush regime, the Obama regime has a penchant for rewarding Justice (sic) Department officials who trample all over the US Constitution. Last year America’s First Black President nominated David Barron to be a judge on the First US Circuit Court of Appeals in Boston.

Barron is responsible for the Justice (sic) Department memo that gave the legal OK for Obama to murder a US citizen with a missile fired from a drone. The execution took place without charges presented to a c...



more from Tyler

Chart School

Sellers Make Late Claim

Courtesy of Declan.

Traders hadn't forgotten the events of last week and were quick to sell their positions in the face of tomorrow's NFP data.

Today's close in the S&P left a bearish inverse doji (gravestone doji), marking supply above 1,950. Bears will feel confident heading into tomorrow's data, assuming Thursday's 1,975 high is not breached. The downside target is a retest of 1,867. A move higher will set up a challenge of 2,044.


The Nasdaq had a quieter day. It didn't suffer the same wide range as the S&P, but today's close finished with a bearish 'cloud cover' over yesterday's trading. Shorts will be liking the risk:reward for a ret...

more from Chart School

All About Trends

Mid-Day Update

Reminder: David is available to chat with Members, comments are found below each post.

Click here for the full report.




To learn more, sign up for David's free newsletter and receive the free report from All About Trends - "How To Outperform 90% Of Wall Street With Just $500 A Week." Tell David PSW sent you. - Ilene...

more from David

Kimble Charting Solutions

Change investment allocations due to .2% of a move?

Courtesy of Chris Kimble.

Can you believe that its a really big deal to some if an index is down 9.9% from it highs (non correction territory) or if its down 10.1% (correction territory).  Does .2% constitute that we make a different allocation decision? Are you kidding me?

Do you find yourself agreeing more with the person on the left or right? I am in the camp with Lou on the right. Should we make investment decisions based upon a term (correction)? Not me

CLICK ON CHART TO ENLARGE

This chart looks at the Dow since 2010 ...



more from Kimble C.S.

OpTrader

Swing trading portfolio - week of August 31st, 2015

Reminder: OpTrader is available to chat with Members, comments are found below each post.

 

This post is for all our live virtual trade ideas and daily comments. Please click on "comments" below to follow our live discussion. All of our current  trades are listed in the spreadsheet below, with entry price (1/2 in and All in), and exit prices (1/3 out, 2/3 out, and All out).

We also indicate our stop, which is most of the time the "5 day moving average". All trades, unless indicated, are front-month ATM options. 

Please feel free to participate in the discussion and ask any questions you might have about this virtual portfolio, by clicking on the "comments" link right below.

To learn more about the swing trading virtual portfolio (strategy, performance, FAQ, etc.), please click here ...



more from OpTrader

Sabrient

Sector Detector: Finally, market capitulation gives bulls a real test of conviction, plus perhaps a buying opportunity

Reminder: Sabrient is available to chat with Members, comments are found below each post.

Courtesy of Sabrient Systems and Gradient Analytics

The dark veil around China is creating a little too much uncertainty for investors, with the usual fear mongers piling on and sending the vast buy-the-dip crowd running for the sidelines until the smoke clears. Furthermore, Sabrient’s fundamentals-based SectorCast rankings have been flashing near-term defensive signals. The end result is a long overdue capitulation event that has left no market segment unscathed in its mass carnage. The historically long technical consolidation finally came to the point of having to break one way or the other, and it decided to break hard to the downside, actually testing the lows from last ...



more from Sabrient

ValueWalk

Some Hedge Funds "Hedged" During Stock Market Sell Off, Others Not As Risk Focused

By Mark Melin. Originally published at ValueWalk.

With the VIX index jumping 120 percent on a weekly basis, the most in its history, and with the index measuring volatility or "fear" up near 47 percent on the day, one might think professional investors might be concerned. While the sell off did surprise some, certain hedge fund managers have started to dip their toes in the water to buy stocks they have on their accumulation list, while other algorithmic strategies are actually prospering in this volatile but generally consistently trending market.

Stock market sell off surprises some while others were prepared and are hedged prospering

While so...



more from ValueWalk

Digital Currencies

Bitcoin Battered After "Governance Coup"

Courtesy of ZeroHedge. View original post here.

Naysyers are warning that the recent plunge in Bitcoin prices - from almost $318 at its peak during the Greek crisis, to $221 yesterday - is due to growing power struggle over the future of the cryptocurrency that is dividing its lead developers. On Saturday, a rival version of the current software was released by two bitcoin big guns. As Reuters reports, Bitcoin XT would increase the block size to 8 megabytes enabling more transactions to be processed every second. Those who oppose Bitcoin XT say the bigger block size jeopardizes the vision of a decentralized payments system that bitcoin is built on with some believing ...



more from Bitcoin

Pharmboy

Baxter's Spinoff

Reminder: Pharmboy and Ilene are available to chat with Members, comments are found below each post.

Baxter Int. (BAX) is splitting off its BioSciences division into a new company called Baxalta. Shares of Baxalta will be given as a tax-free dividend, in the ratio of one to one, to BAX holders on record on June 17, 2015. That means, if you want to receive the Baxalta dividend, you need to buy the stock this week (on or before June 12).

The Baxalta Spinoff

By Ilene with Trevor of Lowenthal Capital Partners and Paul Price

In its recent filing with the SEC, Baxter provides:

“This information statement is being ...



more from Pharmboy

Mapping The Market

An update on oil proxies

Courtesy of Jean-Luc Saillard

Back in December, I wrote a post on my blog where I compared the performances of various ETFs related to the oil industry. I was looking for the best possible proxy to match the moves of oil prices if you didn't want to play with futures. At the time, I concluded that for medium term trades, USO and the leveraged ETFs UCO and SCO were the most promising. Longer term, broader ETFs like OIH and XLE might make better investment if oil prices do recover to more profitable prices since ETF linked to futures like USO, UCO and SCO do suffer from decay. It also seemed that DIG and DUG could be promising if OIH could recover as it should with the price of oil, but that they don't make a good proxy for the price of oil itself. 

Since...



more from M.T.M.

Promotions

Watch the Phil Davis Special on Money Talk on BNN TV!

Kim Parlee interviews Phil on Money Talk. Be sure to watch the replays if you missed the show live on Wednesday night (it was recorded on Monday). As usual, Phil provides an excellent program packed with macro analysis, important lessons and trading ideas. ~ Ilene

 

The replay is now available on BNN's website. For the three part series, click on the links below. 

Part 1 is here (discussing the macro outlook for the markets) Part 2 is here. (discussing our main trading strategies) Part 3 is here. (reviewing our pick of th...

more from Promotions

Help One Of Our Own PSW Members

"Hello PSW Members –

This is a non-trading topic, but I wanted to post it during trading hours so as many eyes can see it as possible.  Feel free to contact me directly at jennifersurovy@yahoo.com with any questions.

Last fall there was some discussion on the PSW board regarding setting up a YouCaring donation page for a PSW member, Shadowfax. Since then, we have been looking into ways to help get him additional medical services and to pay down his medical debts.  After following those leads, we are ready to move ahead with the YouCaring site. (Link is posted below.)  Any help you can give will be greatly appreciated; not only to help aid in his medical bill debt, but to also show what a great community this group is.

http://www.youcaring.com/medical-fundraiser/help-get-shadowfax-out-from-the-darkness-of-medical-bills-/126743

Thank you for you time!




FeedTheBull - Top Stock market and Finance Sites



About Phil:

Philip R. Davis is a founder Phil's Stock World, a stock and options trading site that teaches the art of options trading to newcomers and devises advanced strategies for expert traders...

Learn more About Phil >>


As Seen On:




About Ilene:

Ilene is editor and affiliate program coordinator for PSW. She manages the site market shadows, archives, more. Contact Ilene to learn about our affiliate and content sharing programs.

Market Shadows >>